Top Health Tech Companies in Melbourne (49)
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Top line is described as expanding steadily in recent years, with continued growth expected. Separate reporting cites roughly $500 million in annual revenue and rapid momentum, even as exact figures vary.
Healthy Cash Flow: Cash generation has improved enough for a late‑2025 credit rating upgrade, with projections to produce over $100 million in free cash flow within the next 12–24 months. Leverage is expected to trend down alongside strong margins.
Customer Loyalty & Retention: Retention is characterized as consistently high with net expansion of spend, signaling durable relationships and effective cross‑sell within the installed base. A sizable customer count (over 4,000 organizations) supports stickiness across regions.
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.
Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.
Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.
_0.png)
AlayaCare offers an end-to-end, cloud based platform for home and community-based care agencies and organizations to manage the entire client lifecycle from referrals and intake to billing, payroll, optimized visit scheduling, secure data analytics, and beyond. Combining traditional in-home and virtual care solutions, AlayaCare removes repetitive tasks, enabling care providers across the world to propel towards innovation and homecare of...
Mable is a health-tech platform where people looking for disability and aged care support connect with independent support workers in their community. As one of Australia’s fastest-growing scale-ups, we think big to spearhead change in our sector. We're passionate about inclusivity and giving choice and control back to those who need it. Mable launched in 2014 when co-founder Peter Scutt...
Lyrebird Health is an AI medical scribe that securely listens in the background throughout your consultation, then intelligently generates a note tailored to your style, ready to transfer into the medical record. We're on a mission to automate all non-patient-facing work so that doctors can spend more time with patients and less time on paperwork.
Montu is Australia's leading health tech business revolutionising the alternative health landscape. Montu has built an integrated ecosystem, which streamlines the experience for patients end-to-end, and sets new standards. The company is committed to improve the lives of millions of patients
St Vincent's Health Australia is Australia's largest not-for-profit provider of health and aged care services, operating public and private hospitals, residential aged care, and community and virtual care programs.
MedHealth is a purpose-built collection of industry-leading health, medical, and employment brands that leverage diverse capabilities to deliver optimal health and employment outcomes for the people and communities they support.
Medtronic is a global healthcare solutions company operating in approximately 160 countries. We are committed to improving lives through our medical technologies, services, and solutions. Since our beginning, 60 years ago, our Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. The Mission is our ethical framework and inspirational goal guiding...
Medtronic's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue accelerated to the fastest annual pace in a decade in FY2026, with momentum evident into the fourth quarter. Management’s outlook points to continued upper single‑digit organic expansion in the coming year.
Healthy Cash Flow: Strong free cash flow and a long-running pattern of dividend increases indicate durable cash generation. Recent dividend actions and ongoing cash returns underscore capacity to fund investment and tuck‑in M&A.
Strong Market Position & Advantage: Scale leadership at the top of global medtech by revenue, with breadth across Cardiovascular, Neuroscience, and Medical Surgical, supports resilience. Category strength in areas like cardiac pacing and ablation provides commercial leverage for new launches.
Integral Diagnostics is a leading provider of medical imaging services across Australia and New Zealand, offering a comprehensive range of diagnostic modalities including MRI, CT, X-ray, and ultrasound.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to...
Moderna's Top Stability & Growth Strengths
Innovation-Driven Growth: The company is positioned as a leader in mRNA medicine with multiple late-stage respiratory and oncology programs that could expand beyond COVID into new indications. Acceptance of the flu BLA and positive Phase 3 data for a flu+COVID combo create concrete approval catalysts that could broaden the seasonal franchise if reviews are favorable.
Product Line Growth: The business is transitioning from a single declining product toward a multi-product portfolio, with RSV, next-gen COVID, flu, and combo vaccines advancing toward targeted 2026 approvals. Management’s expectation of modest revenue growth in 2026, with no flu or flu/COVID revenue assumed, implies potential upside if launches land on time.
Strong Market Position & Advantage: The company has demonstrated platform leadership by scaling mRNA globally during COVID and securing a non-COVID mRNA vaccine approval with mRESVIA, including a label expansion to certain higher-risk adults. Settlement of the lipid-nanoparticle patent dispute removes a major legal overhang, improving focus and visibility for launches and late-stage execution.
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world....
HotDoc is Australia's largest and most trusted patient engagement platform. We take pride in helping over 21,000 practitioners connect with more than 9 million patients. The HotDoc platform includes: online bookings, recalls, reminders, check-in, place in queue, online processing of repeat prescription requests, and Inform (a tool designed to encourage patients to take a more proactive interest in preventative health...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 38 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New...
Bupa's Top Stability & Growth Strengths
Strong Revenue Growth: Group results show double‑digit revenue and underlying profit growth in 2024, with customers rising sharply. 2025 materials indicate continued revenue and profit increases alongside a larger customer base, with growth remaining solid even excluding first‑time consolidation effects.
Strong Market Position & Advantage: Independent market analysis places Bupa as the UK PMI leader within a concentrated 'big four', and official statistics show it as the largest fund in Australian private health insurance. Bupa Global is viewed as a tier‑one IPMI provider, and the insurer‑plus‑provider model strengthens competitive positioning across multiple regions.
Market Expansion: Company updates highlight ongoing expansion of clinics, dental centres, hospitals and digital health (Blua), with dozens of new sites opened in 2024 and further additions in 2025. Portfolio moves such as consolidating Niva Bupa in India and adding UK provision assets broaden reach into fast‑growing markets and channels.
Lenexa Medical is an Australian-based MedTech company that has developed the LenexaCARE technology to empower clinicians to deliver targeted, long-term solutions for personalised pressure injury prevention and patient monitoring. Pressure injuries are mostly preventable, however affect millions of people globally each year whilst costing healthcare systems billions of dollars worldwide. In 2020, Australian public hospitals spent over $9 billion to...
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
